Devyser and QIAGEN collaborate on pre-analytical workflow for fetal RHD screening
Fetal derived cell-free DNA (cfDNA) is a key analyte for determining fetal RHD status in plasma...
Podcast
Podcast | December 6, 2022
This episode is dedicated to the 10-year anniversary of Genomics England's 100,000 Genomes Project hosted by Precision Medicine Forum. It's the second of 4 interviews released this week as a celebration. In this episode, they interviewed two of our colleagues Dan Hauzenberger and Turid Sundin Carlsson about the importance of collaborative work, 'homebrew assays', and a future with preventative healthcare.
You can listen to the episode here --> Precision Medicine Forum Podcast - Episode 16
Fetal derived cell-free DNA (cfDNA) is a key analyte for determining fetal RHD status in plasma...
Read More
Devyser is today announcing that its product for non-invasive fetal RHD testing has been granted...
Read More
“The first quarter of the year saw continued strong growth, record gross margin and the launching...
Read More
Devyser is today announcing that the company’s clinical testing laboratory in Roswell in Atlanta,...
Read More